-
Je něco špatně v tomto záznamu ?
Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016
MJ. Dowzicky, E. Chmelařová,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antibakteriální látky farmakologie MeSH
- bakteriální léková rezistence MeSH
- dospělí MeSH
- gramnegativní bakteriální infekce mikrobiologie MeSH
- gramnegativní bakterie klasifikace účinky léků genetika izolace a purifikace MeSH
- grampozitivní bakteriální infekce mikrobiologie MeSH
- grampozitivní bakterie klasifikace účinky léků genetika izolace a purifikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- tigecyklin farmakologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- východní Evropa MeSH
OBJECTIVES: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance programme monitoring the in vitro activity of a panel of antimicrobial agents against clinically important bacterial isolates. Data for Gram-positive and Gram-negative isolates collected in Eastern Europe between 2011 and 2016 are presented here. METHODS: Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method using CLSI guidelines. Antimicrobial susceptibility was assessed using EUCAST breakpoints. RESULTS: Nine Eastern European countries submitted 4289 isolates. Among Acinetobacter baumannii, resistance to levofloxacin, amikacin and meropenem was 77.5%, 63.4% and 62.2%, respectively. Multidrug resistance among A. baumannii was higher in 2015 than in previous years (44.1% in 2011 and 71.0% in 2015), decreasing to 51.7% in 2016. The multidrug resistance percentage for Pseudomonas aeruginosa was 26.9% and was relatively stable over time. The percentage of extended-spectrum β-lactamase (ESBL)-positive isolates among Escherichia coli and Klebsiella pneumoniae was 20.1% and 55.7%, respectively. Resistance to amikacin, meropenem and tigecycline was low among E. coli and K. pneumoniae and the ESBL-producing subset (≤5.9%). Among Staphylococcus aureus isolates, 36.7% were methicillin-resistant (MRSA); percentages varied year-on-year. No S. aureus isolates, including MRSA, were resistant to linezolid, vancomycin or tigecycline. Among Enterococcus faecium isolates, resistance was 22.6% to vancomycin and 2.3% to linezolid; no isolates were resistant to tigecycline. CONCLUSION: This study shows low resistance to meropenem and tigecycline among Enterobacteriaceae isolates and continued activity of linezolid, vancomycin and tigecycline against Gram-positive organisms. However, antimicrobial resistance continues to be problematic in Eastern Europe and requires continued surveillance.
Department of Microbiology AGEL Laboratories Ostrava Vítkovice Czech Republic
Pfizer Inc 500 Arcola Road E Dock Office F 3232 Collegeville PA 19426 USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023906
- 003
- CZ-PrNML
- 005
- 20201214131640.0
- 007
- ta
- 008
- 201125s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jgar.2018.11.007 $2 doi
- 035 __
- $a (PubMed)30445209
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dowzicky, Michael J $u Pfizer, Inc., 500 Arcola Road, E Dock, Office F-3232, Collegeville, PA 19426, USA. Electronic address: Michael.Dowzicky@pfizer.com.
- 245 10
- $a Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016 / $c MJ. Dowzicky, E. Chmelařová,
- 520 9_
- $a OBJECTIVES: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance programme monitoring the in vitro activity of a panel of antimicrobial agents against clinically important bacterial isolates. Data for Gram-positive and Gram-negative isolates collected in Eastern Europe between 2011 and 2016 are presented here. METHODS: Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method using CLSI guidelines. Antimicrobial susceptibility was assessed using EUCAST breakpoints. RESULTS: Nine Eastern European countries submitted 4289 isolates. Among Acinetobacter baumannii, resistance to levofloxacin, amikacin and meropenem was 77.5%, 63.4% and 62.2%, respectively. Multidrug resistance among A. baumannii was higher in 2015 than in previous years (44.1% in 2011 and 71.0% in 2015), decreasing to 51.7% in 2016. The multidrug resistance percentage for Pseudomonas aeruginosa was 26.9% and was relatively stable over time. The percentage of extended-spectrum β-lactamase (ESBL)-positive isolates among Escherichia coli and Klebsiella pneumoniae was 20.1% and 55.7%, respectively. Resistance to amikacin, meropenem and tigecycline was low among E. coli and K. pneumoniae and the ESBL-producing subset (≤5.9%). Among Staphylococcus aureus isolates, 36.7% were methicillin-resistant (MRSA); percentages varied year-on-year. No S. aureus isolates, including MRSA, were resistant to linezolid, vancomycin or tigecycline. Among Enterococcus faecium isolates, resistance was 22.6% to vancomycin and 2.3% to linezolid; no isolates were resistant to tigecycline. CONCLUSION: This study shows low resistance to meropenem and tigecycline among Enterobacteriaceae isolates and continued activity of linezolid, vancomycin and tigecycline against Gram-positive organisms. However, antimicrobial resistance continues to be problematic in Eastern Europe and requires continued surveillance.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a bakteriální léková rezistence $7 D024881
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a gramnegativní bakterie $x klasifikace $x účinky léků $x genetika $x izolace a purifikace $7 D006090
- 650 _2
- $a gramnegativní bakteriální infekce $x mikrobiologie $7 D016905
- 650 _2
- $a grampozitivní bakterie $x klasifikace $x účinky léků $x genetika $x izolace a purifikace $7 D006094
- 650 _2
- $a grampozitivní bakteriální infekce $x mikrobiologie $7 D016908
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a tigecyklin $x farmakologie $7 D000078304
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a východní Evropa $7 D005061
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chmelařová, Eva $u Department of Microbiology, AGEL Laboratories, Ostrava - Vítkovice, Czech Republic.
- 773 0_
- $w MED00198738 $t Journal of global antimicrobial resistance $x 2213-7173 $g Roč. 17, č. - (2019), s. 44-52
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30445209 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131638 $b ABA008
- 999 __
- $a ok $b bmc $g 1596225 $s 1114582
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 17 $c - $d 44-52 $e 20181113 $i 2213-7173 $m Journal of global antimicrobial resistance (Print) $n J Glob Antimicrob Resist $x MED00198738
- LZP __
- $a Pubmed-20201125
